Clinical Trial Update: Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA [Phase 4]

View source ↗

Summary

Phase 4 trial update on long-term safety and efficacy of empagliflozin added to a GLP-1 receptor agonist in adults with type 2 diabetes mellitus; results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Empagliflozin (empagliflozin)
• GLP-1 receptor agonist

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Diabetes Mellitus, Type 2 | Phase 4 | Status: COMPLETED | Results posted: 2019-01-07